Granisetron Fresenius Kabi

Granisetron Fresenius Kabi is an injectable solution containing granisetron hydrochloride as the active ingredient. It is supplied in a sterile liquid form for intravenous administration. The product is marketed in the European Union and is classified as a prescription‑only 5‑HT3 receptor antagonist used to prevent nausea and vomiting associated with chemotherapy and surgery. It is provided in a single‑use vial and is stored under refrigeration until use.

Granisetron Fresenius Kabi is indicated for the prevention of nausea and vomiting in specific clinical settings.

- Prevention of acute and delayed chemotherapy‑induced nausea and vomiting (CINV) in adult patients. - Prevention of postoperative nausea and vomiting (PONV) following general anesthesia. - Adjunct therapy for patients receiving highly emetogenic cancer treatments. - Use in combination with other antiemetic agents when single‑drug control is insufficient.

The safety profile of granisetron includes both frequently observed and rare adverse reactions.

Common: - Headache, usually mild and transient, occurring shortly after infusion. - Constipation or reduced bowel movements, often manageable with diet or laxatives. - Fatigue or a general feeling of weakness that resolves within 24 hours. - Transient dizziness or light‑headedness, especially when standing quickly.

Serious: - Severe allergic reaction (anaphylaxis) presenting with rash, facial swelling, bronchospasm, or difficulty breathing, requiring immediate medical attention. - Cardiac arrhythmia, including irregular heartbeat or palpitations, observed in patients with pre‑existing heart conditions. - Prolonged QT interval on electrocardiogram, which may increase the risk of ventricular tachycardia or torsades de pointes.

When prescribing granisetron, clinicians should consider several precautionary measures to ensure safe use.

- Assess patient history for hypersensitivity to granisetron or other 5‑HT3 antagonists. - Use caution in patients with known cardiac conduction disorders or a history of prolonged QT interval. - Monitor electrolyte balance, especially potassium and magnesium, as abnormalities can exacerbate QT prolongation. - Adjust dose or avoid use in severe hepatic impairment due to reduced drug clearance. - Evaluate concomitant use of other medications that may affect cardiac rhythm. - Consider pregnancy and lactation status; safety data are limited, and benefits must outweigh potential risks.

Granisetron may interact with other drugs; understanding these interactions helps minimize adverse effects.

Avoid: - Co‑administration with other QT‑prolonging agents (e.g., certain antiarrhythmics, antipsychotics, macrolide antibiotics) should be avoided. - Use with potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) may increase granisetron plasma levels and should be avoided.

Use with caution: - Concurrent use of other serotonergic agents (e.g., ondansetron, dexamethasone) may increase the risk of serotonin syndrome; monitor patients. - Combining with other antiemetics that have overlapping mechanisms may enhance efficacy but requires dose adjustment. - Caution when administered with drugs that affect hepatic metabolism, such as rifampin, which may reduce granisetron exposure. - Use cautiously in patients receiving diuretics that may cause electrolyte disturbances influencing cardiac repolarization.